Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
Authors:
- Sun M. LeeSLSun M. Lee
- Laurice K. FischerLFLaurice K. Fischer
- 1 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 39 (10) , 1395-1403
Abstract
Negative-margin resection is crucial to favorable prognosis in patients with pancreatic ductal adenocarcinoma. However, the definition of a negative superior mesenteric artery margin (SMAM) varies. The College of American Pathologists defines positive SMAM as the presence of tumor cells at the margin, whereas the European protocol is based on a 1 mm clearance. In this study, we examined the prognostic significance of the SMAM distance in 411 consecutive pancreatic ductal adenocarcinoma patients who completed neoadjuvant therapy and pancreaticoduodenectomy. Per College of American Pathologists criteria, 32 (7.8%) had positive margins, and 379 (92.2%) had negative margins. Among margin-negative group, SMAM was ≤1, 1.0 to 5.0, and >5.0 mm in 66, 145, and 168 patients, respectively. There was no difference in either disease-free survival (DFS) or overall survival (OS) between the positive-margin group and SMAM≤1 mm (P>0.05). However, patients with SMAM 1.0 to 5.0 mm had better OS than those with positive margins or SMAM≤1 mm (P=0.02). Patients with SMAM>5.0 mm had better DFS and OS than those with SMAM 1.0 to 5.0 mm and those with positive margins or SMAM≤1 mm (PP1 mm for R0 resection in posttherapy pancreaticoduodenectomy specimens.Keywords
This publication has 19 references indexed in Scilit:
- Implicaciones pronósticas del estudio estandarizado de los márgenes de resección en el cáncer de páncreasCirugía Española, 2014
- R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine useSurgery, 2012
- Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiationCancer, 2011
- Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic CancerJournal of Gastrointestinal Surgery, 2011
- Pancreatic cancerThe Lancet, 2011
- Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic HeadJournal of Clinical Oncology, 2008
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic HeadJournal of Clinical Oncology, 2008
- Most Pancreatic Cancer Resections are R1 ResectionsAnnals of Surgical Oncology, 2008
- Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factorBMC Cancer, 2008
- Redefining the R1 resection in pancreatic cancerBritish Journal of Surgery, 2006